Command Palette

Search for a command to run...

INDOCO
303.5(+5.64%)
1W: -1.59%

Indoco Remedies Peer Comparison

Snapshot Summary

Indoco Remedies Ltd. shows moderate growth and profitability metrics compared to its peers in the pharmaceuticals sector. While it has a reasonable debt level, its negative EPS and PE ratio indicate significant challenges. Companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. stand out with their robust financial profiles, while Indoco may be viewed as a value pick due to its lower valuation metrics despite the negative earnings. Overall, the sector is competitive with a mix of strong performers and some financially weak entities.

  • Indoco Remedies has a negative PE ratio and low revenue growth compared to peers.
  • Cipla and Dr. Reddy's are top performers in profitability and efficiency metrics.
  • Several companies are overvalued based on high PE ratios despite decent growth.
  • Cipla Ltd.: Highest ROE (16.63%) and good revenue growth (13.28% YoY) with a low PE of 23.73.
  • Dr. Reddy's Laboratories Ltd.: Strong profitability with high ROE (21.76%) and low PEG ratio (0.19), indicating good growth potential.
Stocks
CMP
Market Cap
P/E
ROCE (%)
Debt/Equity
INDOCO₹267.05₹2,463.48Cr-47.6111.25%0.59
SUNPHARMA₹1,563.35₹3,75,099.26Cr87.5917.60%0.04
DIVISLAB₹6,091.05₹1,61,698.50Cr73.2016.46%-
CIPLA₹1,587.60₹1,28,217.27Cr23.7322.77%0.01
TORNTPHARM₹3,581.55₹1,21,215.77Cr61.5324.28%0.57
DRREDDY₹1,280.30₹1,06,835.27Cr15.5026.86%0.07
MANKIND₹2,518.95₹1,03,926.59Cr55.1828.38%0.02

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.